Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US).
Wildner D, Heinzerling L, Scheulen ME, Kaempgen E, Schuler G, Strobel D, Janka R, Neurath MF, Sturm J, Knieling F. Wildner D, et al. Among authors: schuler g. J Cancer Res Clin Oncol. 2022 Apr;148(4):955-965. doi: 10.1007/s00432-021-03666-8. Epub 2021 May 28. J Cancer Res Clin Oncol. 2022. PMID: 34050396 Free PMC article.
Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.
Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G, Schuler-Thurner B, Heinzerling L. Voskens C, et al. Among authors: schuler g, schuler thurner b. J Clin Oncol. 2012 Nov 20;30(33):e356-7. doi: 10.1200/JCO.2011.41.4359. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045571 No abstract available.
Can checkpoint inhibitor therapy improve response to chemotherapy?
Kirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L. Kirchberger MC, et al. Among authors: schuler g. J Cancer Res Clin Oncol. 2018 Jan;144(1):183-185. doi: 10.1007/s00432-017-2546-8. Epub 2017 Nov 24. J Cancer Res Clin Oncol. 2018. PMID: 29177557 No abstract available.
C-reactive protein as an early marker of immune-related adverse events.
Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. Abolhassani AR, et al. Among authors: schuler g. J Cancer Res Clin Oncol. 2019 Oct;145(10):2625-2631. doi: 10.1007/s00432-019-03002-1. Epub 2019 Sep 6. J Cancer Res Clin Oncol. 2019. PMID: 31492984
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L. Brüggemann C, et al. Among authors: schuler g. J Cancer Res Clin Oncol. 2017 Oct;143(10):1977-1984. doi: 10.1007/s00432-017-2450-2. Epub 2017 Jun 14. J Cancer Res Clin Oncol. 2017. PMID: 28616701
Senescence markers: Predictive for response to checkpoint inhibitors.
Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L. Moreira A, et al. Among authors: schuler g. Int J Cancer. 2019 Mar 1;144(5):1147-1150. doi: 10.1002/ijc.31763. Epub 2018 Dec 4. Int J Cancer. 2019. PMID: 30151962 Free article.
1,272 results